EUVIMEDEUVIMED entdecken
Open Access

Methodologic Approach to Defining Comorbidities in a Cohort of Patients With Cancer: An Example in the Optimal Breast Cancer Chemotherapy Dosing Study

Peng Wang iD, Kelli O'Connell iD, Jenna Bhimani iD, Victoria Blinder iD, Rachael Burganowski iD, Isaac J Ergas iD, Grace B Gallagher iD, Jennifer J Griggs iD, Narre Heon iD, Tatjana Kolevska, Yuriy Kotsurovskyy, Candyce H Kroenke iD und 12 weitere

JCO Clinical Cancer Informatics · 2025

DOI: 10.1200/cci-24-00231 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Clinical Cancer Informatics, 2025. Verfasst von Peng Wang und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE We evaluated the definitions of five comorbidities (renal and hepatic impairments, anemia, neutropenia, and thrombocytopenia) in women with breast cancer using data from electronic health records. METHODS In 11,097 women receiving adjuvant chemotherapy for stage I-IIIA breast cancer at Kaiser Permanente Northern California or Kaiser Permanente Washington, we assessed comorbidity definitions in two commonly used lookback windows (1 year before diagnosis, T1; and extending until chemotherapy initiation, T1-2). Within each, we assessed data availability and agreement between International Classification of Diseases (ICD)–defined and lab-defined comorbidities of varying severity. To assess how different pieces of information may affect providers in making treatment decisions, we used multivariable logistic regression to evaluate four-category (with comorbidity indicated by both ICD and lab, ICD-only, lab-only, or neither) and collapsed binary (comorbidity indicated by either ICD or lab v neither) definitions in relation to first cycle chemotherapy dose reduction (FCDR). RESULTS Extending the lookback period to chemotherapy initiation increased laboratory data availability (missingness ≤4.1% in T1-2 v >40% in T1). Assessment of agreement guided selection of laboratory cutpoints. In both time periods, the four-category and binary comorbidity variables were associated with use of FCDR, but binary variables had larger cell sizes and more stability of regression models. Ultimately, the comorbidity variables in T1 were defined by a combination of either ICD/qualifying laboratory values. Results were similar in T1-2, except laboratory data alone outperformed the combination variable for renal and hepatic comorbidity. CONCLUSION Leveraging both ICD and lab data and extending the lookback period to include postdiagnosis but prechemotherapy initiation may provide better capture of comorbidity. Future studies may consider validating our findings with a gold-standard comorbidity status and in other community health care settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleComorbidityMiddle AgedAgedElectronic Health RecordsAdultCohort StudiesChemotherapy, Adjuvant

Autor:innen und Institutionen

  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA.
  • Division of Research, Kaiser Permanente Northern California, Pleasanton, CA.
  • Department of Medicine, Division of Hematology/Oncology and Department of Health Management and Policy, University of Michigan, Ann Arbor, MI.
  • Department of Oncology, Kaiser Permanente Medical Center, Vallejo, CA.

ORCID-Profile: Peng Wang, Kelli O'Connell, Jenna Bhimani, Victoria Blinder, Rachael Burganowski, Isaac J Ergas, Grace B Gallagher, Jennifer J Griggs, Narre Heon, Candyce H Kroenke, Cecile A Laurent, Raymond Liu, Kanichi G Nakata, Sonia Persaud, Donna R Rivera, Janise M Roh, Sara Tabatabai, Emily Valice, Elisa V Bandera, Lawrence H Kushi, Erin J Aiello Bowles, Elizabeth D Kantor

Förderung

  • NCI NIH HHS

Zitieren

APA

Wang, P., O'Connell, K., Bhimani, J., Blinder, V., Burganowski, R., Ergas, I. J., Gallagher, G. B., Griggs, J. J., Heon, N., Kolevska, T., Kotsurovskyy, Y., Kroenke, C. H., Laurent, C. A., Liu, R., Nakata, K. G., Persaud, S., Rivera, D. R., Roh, J. M., Tabatabai, S., …, & Kantor, E. D. (2025). Methodologic Approach to Defining Comorbidities in a Cohort of Patients With Cancer: An Example in the Optimal Breast Cancer Chemotherapy Dosing Study. JCO Clinical Cancer Informatics. https://doi.org/10.1200/cci-24-00231

Vancouver

Wang P, O'Connell K, Bhimani J, Blinder V, Burganowski R, Ergas IJ, et al. Methodologic Approach to Defining Comorbidities in a Cohort of Patients With Cancer: An Example in the Optimal Breast Cancer Chemotherapy Dosing Study. JCO Clinical Cancer Informatics. 2025. doi:10.1200/cci-24-00231

BibTeX
@article{Wang2025,
  author = {Wang, Peng and O'Connell, Kelli and Bhimani, Jenna and Blinder, Victoria and Burganowski, Rachael and Ergas, Isaac J and Gallagher, Grace B and Griggs, Jennifer J and Heon, Narre and Kolevska, Tatjana and Kotsurovskyy, Yuriy and Kroenke, Candyce H and Laurent, Cecile A and Liu, Raymond and Nakata, Kanichi G and Persaud, Sonia and Rivera, Donna R and Roh, Janise M and Tabatabai, Sara and Valice, Emily and Bandera, Elisa V and Kushi, Lawrence H and Aiello Bowles, Erin J and Kantor, Elizabeth D},
  title = {Methodologic Approach to Defining Comorbidities in a Cohort of Patients With Cancer: An Example in the Optimal Breast Cancer Chemotherapy Dosing Study},
  journal = {JCO Clinical Cancer Informatics},
  year = {2025},
  doi = {10.1200/cci-24-00231}
}
Kostenlos starten →